Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Flagyl I.V.. Every FDA application for this active ingredient: 1 branded and 1 generic. Boxed warning
As of Nov 22, 2026, FDA lists 2 applications for Metronidazole hydrochloride (sold as Flagyl I.V.), first approved Nov 28, 1980, with 1 new use approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
AnaemetroA drug with a new additional pediatric dosage indicated for the treatment of anaerobic infection (sepsis, deep skin infection, secondary infections of… · Pfizer Japan Inc. · Nov 20, 2025
RozexA drug with a new indication and a new dosage for the treatment of rosacea. · Maruho Co., Ltd. · May 26, 2022
Rozex, new approvalA drug with a new route of administration indicated for disinfection/deodorisation of odorous fungating tumours. · Galderma S.A. · Dec 26, 2014
Anaemetro, new approvalA drug with a new route of administration indicated for the treatment of different kinds of anaerobic bacterial infections, infectious enteritis, and amebic… · Pfizer Japan Inc. · Jul 4, 2014
FlagylA drug with new additional indications and a new dosage for the treatment of anaerobic bacterial infection, infectious enteritis, amoebic dysentery, and… · Shionogi & Co., Ltd. · Aug 10, 2012
FlagylDrugs with a new indication and new dosages for the treatment of bacterial vaginosis. · Shionogi & Co., Ltd. · Mar 21, 2012
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA